COPD Clinical Trials -- Stempeutics finishes phase II enrollment


New member
Stempeutics has moved from Phase I/II to Phase II clinical trials in Bangalore, with their Allogenic Mesenchymal Stem cells. Results of Phase II should be published in 2014.

This treatment has already proven effective in repairing lungs for transplant, and Stempeutics will be the first company worldwide, to have an off the shelf product for certain types of lung damage.



Pioneer Founding member
If they are successful, then how long until the U.S. will allow patients access to this product? Will it be like Daxas and other drugs that were approved elsewhere long before the FDA approved them in the U.S. Undoubtedly lengthy clinical trials will be required to help fill the FDA coffers.